Sustained Benefit of Continuous Glucose Monitoring on HbA1c, Glucose Profiles, and Hypoglycemia in Adults with Type 1 Diabetes

  1. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group

    Abstract

    Objective: To evaluate long-term effects of continuous glucose monitoring (CGM) in intensively-treated adults with type 1 diabetes (T1D).

    Research Design and Methods: 83 of 86 individuals ≥25 years old with T1D who used CGM as part of a 6-month randomized clinical trial completed a subsequent 6-month extension study.

    Results: After 12 months, median CGM use was 6.8 days per week. Mean change in HbA1c level from baseline to 12 months was −0.4±0.6% (P<0.001) in subjects with baseline HbA1c ≥7.0%. HbA1c remained stable at 6.4% in those with baseline HbA1c <7.0%. The incidence rate of severe hypoglycemia was 21.8 and 7.1 events per 100 person-years in the first and last 6 months, respectively. Time per day with glucose levels in the range of 71 to 180 mg/dL increased significantly (P=0.02) from baseline to 12 months.

    Conclusions: In intensively-treated adults with T1D, CGM use and benefit can be sustained for 12 months.

    Footnotes

      • Received May 7, 2009.
      • Accepted July 29, 2009.

    This Article

    1. Diabetes Care
    1. Online-Only Appendix
    2. All Versions of this Article:
      1. dc09-0846v1
      2. 32/11/2047 most recent